MHRA Authorises Aujemflu Flu Vaccine for UK Over-50s
On 4 June 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, authorised Aujemflu for adults aged 50 and over in the UK. In regulatory language, this is a marketing authorisation. In everyday language, it means a new flu vaccine has passed the regulator’s checks and can now be used in the UK. If the name sounds dense, that is because medicine often arrives wrapped in specialist terms. The useful task is to translate them. According to the MHRA, Aujemflu is intended to protect older adults against flu, and none of the ingredients in the vaccine can cause flu.
The phrase 'adjuvanted trivalent' looks intimidating, but it becomes clearer once you slow it down. 'Trivalent' means the vaccine is designed to target three strains of influenza, in line with World Health Organisation recommendations for the 2025/2026 season. 'Adjuvanted' means it contains an added substance that helps the immune system build a stronger response. That detail matters for over-50s because vaccine design is not only about which strains are included. It is also about how well the body responds. The MHRA says Aujemflu is given as a single injection into the upper arm by a doctor, nurse or pharmacist.
Another term in the announcement is 'egg-free'. That does not describe what the vaccine protects against. It describes how it is made. The MHRA says Aujemflu is prepared in cell culture rather than in eggs, which means it is a non-egg-based flu vaccine. What this means for you is mostly about understanding the production method. 'Egg-free' is not marketing sparkle and it is not a sign that the vaccine has skipped normal checks. It simply tells you this flu vaccine is made in a different way from some older flu vaccines, while still being assessed by the same regulator for quality, safety and effectiveness.
The approval process is worth pausing on, because this is where many public health stories become fuzzy. The MHRA, which regulates medicines and medical devices in the UK, says it authorised Aujemflu after deciding that the benefits of the vaccine are greater than its risks. The application, according to the agency, was approved under its national assessment procedure. Julian Beach, the MHRA’s Executive Director for Healthcare Quality and Access, said the regulator will keep the vaccine’s safety and effectiveness under close review. That is an important point for readers. Authorisation is not the end of scrutiny. It is the point where a product can be used because the evidence has been judged strong enough, while monitoring continues.
The evidence named by the MHRA came from a study involving 7,699 participants aged 50 and over. Four weeks after vaccination, people who received a quadrivalent version of the same adjuvanted vaccine platform showed a stronger immune response than those who received a quadrivalent adjuvanted egg-based influenza vaccine. The MHRA also says that response was comparable to a quadrivalent recombinant influenza vaccine against three out of four flu strains. That sentence is technical, but the broad message is simpler than it first appears: the regulator is pointing to trial evidence, not guesswork, as the basis for the approval.
For over-50s, the practical message is straightforward. Aujemflu is now an authorised option in the UK, but that does not remove the need to read the Patient Information Leaflet and ask questions if you are unsure about side effects or suitability. The MHRA says patients should speak to a doctor, pharmacist or nurse if they need advice. If you suspect a side effect, the agency encourages people to report it through the Yellow Card scheme as well as talking to a healthcare professional. The marketing authorisation was granted to Seqirus UK Limited, and fuller product information is due to appear on the MHRA Products website within seven days of approval.
If you are trying to make sense of the announcement quickly, it helps to translate the key words into plain English. 'Adjuvanted' means the vaccine includes an ingredient to help the immune response. 'Trivalent' means it targets three flu strains. 'Egg-free' tells you how it is manufactured. 'Authorised' means the UK regulator has judged that the benefits outweigh the risks. That is the real value of an explainer like this. Once the jargon is stripped back, the story is clear: the MHRA has authorised a new egg-free flu vaccine called Aujemflu for UK adults aged 50 and over, and the sensible next step for patients is to read the leaflet, ask a healthcare professional anything they want clarified, and use the Yellow Card system if something does not seem right.